Industry woes
A story, published in April, about Kaleido Biosciences shutting up shop and bluebird bio restructuring got readers' keyboards rattling.
Bleubird bio, among others, noted the “tough biotech market” in 2022, which it saw had taken some traditional financing off the table, in the near term.
Photo credit: GettyImages/Robert Daly